二甲双胍治疗系统性红斑狼疮的安全性与有效性:多中心随机双盲安慰剂对照试验
该多中心随机双盲安慰剂对照试验纳入140例无糖尿病的中国SLE患者,在标准治疗基础上加用二甲双胍或安慰剂,随访12个月。二甲双胍组胃肠道不良事件更多,但感染事件显著减少。研究把握度不足,不能对二甲双胍减少 flare 的疗效得出确切结论,但安全性良好,为更大规模试验提供了依据。
核心结论
- 该试验把握度不足,无法就二甲双胍作为SLE标准治疗附加用药减少疾病 flare 的疗效得出可靠结论。
- 二甲双胍在SLE患者中安全性良好,为在低疾病活动度且复发风险高的SLE患者中开展更大规模试验提供了依据。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,在中国上海三家医院开展。
- 纳入无糖尿病的成人SLE患者,要求SELENA-SLEDAI评分≤6、BILAG量表无A评分且B评分不超过1个、既往至少一次狼疮 flare、前12个月内接受过泼尼松≥20 mg/日治疗。
- 共筛查180例,入组140例(78%),二甲双胍组67例、安慰剂组73例,按1:1区组随机(每区组4例)分配。
- 主要终点为12个月时SELENA-SLEDAI Flare Index复合指数(重度或轻中度疾病 flare)。
主要发现
- 无患者因治疗死亡。
关键数值与推荐
- 主要终点为12个月时SELENA-SLEDAI Flare Index复合指数(重度或轻中度疾病 flare)。
临床怎么用
- 该试验未证实二甲双胍能显著减少狼疮 flare,当前证据不足以支持将其作为SLE常规附加治疗。
- 二甲双胍组感染事件较少,提示其潜在获益值得在更大规模试验中进一步验证。
局限性
- 该试验把握度不足,无法就二甲双胍减少SLE flare 的疗效得出可靠结论。
- 研究仅纳入SELENA-SLEDAI评分≤6的低疾病活动度患者,结论外推至中高疾病活动度人群受限。
- 随访时间为12个月,长期疗效与安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunometabolism is involved in the pathogenesis of systemic lupus erythematosus (SLE). The aim of this study was to repurpose metformin, an anti-diabetic drug that regulates systemic and cellular metabolism, and assess its effects in Chinese patients with SLE without diabetes. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled trial in three hospitals in Shanghai, China. We enrolled adult patients with SLE, without diabetes, who had Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) scores no higher than 6; with no A score or no more than one B score on the British Isles Lupus Assessment Group (BILAG) scale at screening; who had had at least one lupus flare; and were treated with prednisone (≥20 mg per day) within the preceding 12 months. Patients were randomly assigned (1:1) in blocks of four by a computer algorithm to add metformin tablets (250 mg per tablet with a target dose of 0·5 g three times per day; metformin group) or placebo tablets (placebo group) to their standard therapy, for a maximum of 12 months. Patients, assessment staff, and statisticians were masked to group assignment. The primary endpoint was a composite index of major or mild-to-moderate disease flares (SELENA-SLEDAI Flare Index) at 12 months. The full analyses were done in all patients who received at least one dose of the study drug using the χ2 test. Adverse events were recorded during the 12-month follow-up. This study is registered with ClinicalTrials.gov, NCT02741960. FINDINGS: Between May 24, 2016, and Dec 13, 2017, 180 patients were screened, of whom 140 (78%) of them were enrolled. 31 (17%) did not meet the inclusion criteria and nine (5%) withdrew informed consent without treatment after randomisation. 67 patients were assigned to the metformin group and 73 to the placebo group. By 12 months of follow-up, there was no significant difference in the incidence of lupus flares, which occurred in 14 (21%) patients in the metformin group versus 25 (34%) in the placebo group (relative risk 0·68, 0·42-1·04, p=0·078). Patients receiving metformin experienced more gastrointestinal adverse events (three [4%] discontinued for this reason vs one [1%] for placebo; overall 26 [39%] vs 11 [15%], p=0·0015), but the incidence of non-flare serious adverse events was similar between groups (one [1%] vs three [4%], p=0·35). The frequency of infection events was significantly lower in patients in the metformin group than in the placebo group (17 [25%] vs 32 [44%], p=0·022). No patients died as a result of treatment. INTERPRETATION: This trial was underpowered to draw a sound conclusion on the efficacy of metformin to reduce disease flares as an add-on treatment to standard care in patients with SLE. Nonetheless, metformin had a favourable safety profile and our data present a basis for larger trials to investigate its potential effect on reducing the frequency of flares for patients with SLE with low-grade disease activity who are at risk of relapse. FUNDING: Shanghai Shenkang Promoting Project and the National Key Research and Development Program of China.
引用
- Sun F, Wang HJ, Liu Z, et al. Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2020. PMID: 38268156. doi:10.1016/S2665-9913(20)30004-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。